Skip to main content
Skip to main content
VYND logo

Vynleads, Inc. (VYND) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.4098 $0.00 (0.00%) |CouncilSplit View · 50 · B
MCap: $7.51M| Vol: 700| 52-wk range: $0.252 – $0.50

Market cap $7.51M is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Vynleads, Inc. (VYND) trades at $0.4098. Vynleads, Inc. provides health and wellness guidance, nutritional supplements, and a lifestyle newsletter primarily to individuals in the United States managing pre-diabetes or type 2 diabetes. Market cap: $7.51M, Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: Jun 14, 2026
Vynleads, Inc. provides health and wellness guidance, nutritional supplements, and a lifestyle newsletter primarily to individuals in the United States managing pre-diabetes or type 2 diabetes. The company's core offering, the 'Lifestyle Blueprint,' is a digital resource for dietary guidelines and broader nutritional insights, distributed via its online platforms.

Analyst Coverage for VYND: VYND does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VYND against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the VYND film Every key number, told as a short cinematic story — just press play. ~2 min

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Council Score · Weighted Average of 3 Disciplines
Split View 50/100 · B

VYND: the 2 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Englander-style lens (simulated)Izzy Englander
Favorable read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Neutral read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Vynleads, Inc. (VYND) Healthcare & Pipeline Overview

CEOAlex J. Mannine
Employees1
HeadquartersRock Hill, US
IPO Year2020

Vynleads, Inc. specializes in digital health and wellness guidance for pre-diabetic and type 2 diabetic individuals in the U.S., offering an intensive eight-week dietary program, nutritional supplements, and a subscription-based lifestyle newsletter. The company leverages online platforms to deliver its specialized content and products, addressing a significant public health challenge with a focused approach.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 14, 2026

What Is the Investment Thesis for VYND?

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Vynleads, Inc. presents an investment thesis centered on its focused approach to the growing pre-diabetes and type 2 diabetes market within the United States. The company addresses a significant public health challenge by offering digital health and wellness guidance, nutritional supplements, and a subscription-based newsletter. Key value drivers include the increasing prevalence of diabetes, which creates a sustained demand for management solutions, and the company's digital-first distribution model, which offers scalability and direct customer access through platforms like constitutionalhealth.com. The recurring revenue potential from monthly newsletter subscriptions also contributes to a stable business outlook. Growth catalysts for Vynleads include the ongoing expansion of its digital subscriber base and the potential to enhance its product offerings, particularly the 'Lifestyle Blueprint' and nutritional supplements, to capture a larger share of the wellness market. The company's niche specialization allows for targeted marketing and content development. However, the investment carries notable risks, including its small market capitalization of $7.51M and a high Beta of 5.05, indicating significant price volatility. The company's lean operational structure with only one employee and its trading on the OTC market with an 'Unknown' disclosure status also introduce higher operational and transparency risks for investors.

Based on FMP financials and quantitative analysis

VYND Key Highlights

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Vynleads, Inc. operates with a focused business model targeting individuals with pre-diabetes or type 2 diabetes in the U.S.

  • The company maintains a very lean operational structure, employing a single individual, which impacts scalability and operational capacity.
  • Vynleads, Inc. was incorporated in 2015, indicating over a decade of operational history in the health and wellness sector.
  • The company's market capitalization stands at $7.51M, reflecting its status as a micro-cap entity.
  • Vynleads, Inc. exhibits a high Beta of 5.05, suggesting significant volatility relative to the broader market, which is typical for smaller, less liquid securities.

Who Are VYND's Competitors?

VYND is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
MGRX Mangoceuticals, Inc. $0.39 +1.51% $6.63M
BFRG Bullfrog AI Holdings, Inc. Common Stock $0.48 -1.98% $8.82M
SCNX Scienture Holdings, Inc. $0.35 -2.69% $14.1M
BEAT HeartBeam, Inc. $0.40 -2.14% $22.3M
EUDA EUDA Health Holdings Limited $13.12 +0.15% $24.5M
ONMD OneMedNet Corporation $0.67 -1.84% $38.0M
CCLD CareCloud, Inc. $2.04 -3.32% $86.7M 725-pillar
DH Definitive Healthcare Corp. $1.03 0.00% $109M

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VYND's Key Strengths?

Specialized focus on pre-diabetes and type 2 diabetes addresses a significant and growing health concern.

  • Digital-first business model allows for broad reach across the U.S. and efficient content delivery.
  • Offers a diversified product portfolio including digital guidance, supplements, and a subscription newsletter.
  • Established in 2015, indicating over a decade of operational experience in the health sector.

What Are VYND's Weaknesses?

Extremely lean operational structure with only one employee may limit scalability and capacity for growth.

  • Small market capitalization of $7.51M indicates limited financial resources and market influence.
  • High Beta of 5.05 suggests significant stock price volatility, posing higher risk for investors.
  • Trading on the OTC market with 'Unknown' disclosure status implies limited transparency and regulatory oversight.

What Could Drive VYND Stock Higher?

VYND catalyst: Expansion of the subscriber base for the monthly healthy lifestyle newsletter, indicating growing customer engagement and recurring revenue.

  • Continuous development and enhancement of the 'Lifestyle Blueprint' content and features, potentially attracting new users and improving retention.
  • Strategic marketing initiatives to increase awareness and adoption of Vynleads' nutritional supplements within its target demographic.

What Are the Key Risks for VYND?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

  • Intense competition within the broader health and wellness and digital health sectors, potentially limiting market share growth.
  • Regulatory changes or increased scrutiny regarding health claims for dietary programs and nutritional supplements could impact product offerings and marketing strategies.
  • High dependence on its digital platforms for sales and content delivery, making the company vulnerable to technical issues or cybersecurity threats.
  • The company's lean operational structure with only one employee may pose limitations on its ability to scale operations, innovate rapidly, or respond to market changes effectively.
  • Significant stock price volatility due to its high Beta of 5.05 and trading on the less liquid OTC market, increasing investment risk.

What Are the Growth Opportunities for VYND?

  • **Expanding Reach within the Diabetes Management Market:** Vynleads, Inc. has a significant opportunity to expand its market penetration within the pre-diabetes and type 2 diabetes communities in the United States. Given the high prevalence of these conditions, increasing awareness and accessibility of the 'Lifestyle Blueprint' and related services could drive substantial user growth. By leveraging digital marketing and potentially forming partnerships with healthcare providers or wellness programs, Vynleads could reach a broader audience seeking structured dietary guidance and support, thereby increasing subscription and product sales. The digital nature of its offerings allows for scalable expansion without significant physical infrastructure investments.
  • **Diversification and Enhancement of Nutritional Supplement Offerings:** The company currently distributes a selection of nutritional supplements. A key growth opportunity lies in diversifying this product line to address a wider range of health needs pertinent to its target demographic, or by introducing new formulations based on emerging nutritional science. Expanding the supplement portfolio, potentially through strategic sourcing or in-house development if feasible, could increase average customer value and attract new customers seeking specific dietary support. This expansion would leverage Vynleads' existing online distribution channels and customer trust in its health guidance.
  • **Enhancing the 'Lifestyle Blueprint' with Advanced Features and Personalization:** The 'Lifestyle Blueprint' is a core offering. Growth can be achieved by enhancing this online resource with more interactive features, personalized content, or integration with health tracking devices. For instance, incorporating progress tracking, community forums, or one-on-one coaching options could significantly increase user engagement and perceived value, potentially justifying premium pricing or attracting a broader user base. Continuous content updates and evidence-based refinements would also reinforce its credibility and effectiveness.
  • **Expanding the Subscriber Base for the Exclusive Newsletter:** Vynleads' monthly subscription newsletter explores various healthy lifestyle topics. There is an opportunity to significantly grow its subscriber base by enhancing content quality, introducing guest contributors, or offering tiered subscription models with exclusive content. Promoting the newsletter as a continuous educational resource for managing diabetes and overall wellness could attract individuals seeking ongoing support and information beyond the initial 'Lifestyle Blueprint' program, thereby strengthening recurring revenue streams and customer loyalty.
  • **Strategic Partnerships and Affiliate Programs:** Given its specialized focus and digital distribution, Vynleads could explore strategic partnerships with other health and wellness platforms, fitness centers, or even healthcare organizations. Affiliate marketing programs could also incentivize health influencers or related businesses to promote Vynleads' products and services. Such collaborations could significantly expand Vynleads' reach and customer acquisition channels without requiring extensive in-house marketing expenditures, tapping into established audiences and leveraging complementary services to drive growth.

What Threats Does VYND Face?

  • Intense competition from larger healthcare providers, digital health platforms, and supplement companies.
  • Potential for increased regulatory scrutiny on health claims for dietary programs and nutritional supplements.
  • Dependence on digital platforms makes the company vulnerable to cybersecurity risks and website outages.
  • Market volatility and limited liquidity associated with its OTC listing could deter institutional investors.

What Are VYND's Competitive Advantages?

  • **Niche Specialization:** Focused expertise in pre-diabetes and type 2 diabetes management, allowing for tailored content and product development.
  • **Proprietary Content:** The 'Lifestyle Blueprint' and exclusive newsletter represent proprietary intellectual property and specific methodologies.
  • **Direct Digital Distribution:** Control over its online platforms (constitutionalhealth.com, wearedwd.com, dwdprotocol.com) enables direct customer engagement and efficient delivery.
  • **Holistic Approach:** Combines dietary guidance, nutritional supplements, and ongoing educational content for comprehensive support.

What Does VYND Do?

Vynleads, Inc., established in 2015 and headquartered in Rock Hill, South Carolina, operates within the healthcare sector, specifically focusing on medical and healthcare information services. The company's primary mission is to provide comprehensive health and wellness guidance to individuals in the United States who are navigating pre-diabetes or living with type 2 diabetes. This specialized focus allows Vynleads to cater to a distinct and growing demographic with targeted solutions designed to support lifestyle modifications and health management. At the core of Vynleads' offerings is the "Lifestyle Blueprint," an online resource meticulously designed to provide dietary guidelines. This blueprint features an intensive eight-week, very low-calorie regimen, complemented by broader nutritional insights intended to foster sustainable healthy eating habits. The digital nature of this resource ensures accessibility and flexibility for its users, aligning with modern preferences for self-managed health solutions. Beyond informational guidance, Vynleads, Inc. also engages in the distribution of a curated selection of nutritional supplements, which are intended to support the overall health and wellness objectives of its target audience. These supplements are an integral part of the company's holistic approach to diabetes management and prevention. Further diversifying its service portfolio, Vynleads offers monthly subscription access to an exclusive newsletter. This proprietary publication delves into a variety of topics pertinent to maintaining a healthy lifestyle, providing ongoing education and motivation to subscribers. The subscription model establishes a recurring revenue stream and fosters a continuous engagement with its customer base. All of Vynleads' merchandise and digital resources are made available for purchase and access digitally through its dedicated web platforms: constitutionalhealth.com, wearedwd.com, and dwdprotocol.com. This direct-to-consumer digital distribution strategy underscores the company's operational model, allowing it to reach its audience efficiently across the United States. With a lean operational structure, Vynleads, Inc. maintains a focused approach to its niche market within the broader healthcare landscape.

What Products and Services Does VYND Offer?

  • Provides health and wellness guidance to individuals with pre-diabetes or type 2 diabetes.
  • Offers the 'Lifestyle Blueprint,' an online resource with dietary guidelines for an eight-week, very low-calorie regimen.
  • Distributes a selection of nutritional supplements tailored for health and wellness.
  • Provides monthly subscription access to an exclusive newsletter covering healthy lifestyle topics.
  • Sells products and services digitally through its web platforms: constitutionalhealth.com, wearedwd.com, and dwdprotocol.com.
  • Focuses primarily on serving customers within the United States.
  • Aims to support individuals in managing their health through dietary and lifestyle interventions.

How Does VYND Make Money?

  • **Digital Product Sales:** Generates revenue through direct online sales of its 'Lifestyle Blueprint' program, which is an online resource.
  • **Nutritional Supplement Sales:** Earns income from the distribution and sale of various nutritional supplements via its e-commerce platforms.
  • **Subscription Services:** Secures recurring revenue through monthly subscriptions to its exclusive healthy lifestyle newsletter.
  • **Direct-to-Consumer Model:** Utilizes its proprietary websites (constitutionalhealth.com, wearedwd.com, dwdprotocol.com) for all sales and service delivery, eliminating intermediaries.

What Industry Does VYND Operate In?

Vynleads, Inc. operates within the dynamic and expansive healthcare information services industry, specifically targeting the niche of diabetes management and prevention. The broader healthcare sector is experiencing significant growth driven by an aging population, rising chronic disease prevalence, and increasing adoption of digital health solutions. Within this context, Vynleads focuses on the substantial market of individuals with pre-diabetes or type 2 diabetes in the United States. The Centers for Disease Control and Prevention (CDC) reports that over 38 million Americans have diabetes, and approximately 98 million adults have pre-diabetes, highlighting a vast and growing need for effective management and prevention strategies. The competitive landscape for Vynleads is diverse, encompassing a range of players from large pharmaceutical companies with diabetes medications to digital health platforms, wellness apps, and numerous providers of dietary advice and nutritional supplements. Vynleads differentiates itself through its specific focus on an intensive eight-week dietary regimen via its 'Lifestyle Blueprint' and its direct-to-consumer digital distribution. While the market is fragmented, the company's ability to carve out a specialized niche within health guidance and supplement distribution positions it to address a critical, underserved segment of the population seeking proactive health management.

Who Are VYND's Key Customers?

  • Individuals diagnosed with pre-diabetes.
  • Individuals living with type 2 diabetes.
  • Consumers actively seeking health and wellness guidance for lifestyle modification.
  • Customers interested in nutritional supplements to support their health goals.
  • Primarily located within the United States.
Model self-rating on this text: 68% (not a measure of the evidence) Updated: Jun 14, 2026

Research confidence

Low 20/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price is current
  • No filing on record
  • No analyst coverage

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 48
2026-08-26 48
2026-08-29 48
2026-09-01 48
2026-09-04 48
2026-09-07 48
2026-09-10 48

What changed?

The score has stayed at 48.

Over the same 18 days the stock moved +0.0%.

How Vynleads, Inc. Is Valued

Vynleads, Inc. carries a market capitalization of $7.51M, placing it in the micro-cap category.

Company Profile

Vynleads, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Rock Hill, US. The company is led by CEO Alex J. Mannine. VYND has traded publicly since 2020.

ROE 72%

Key Financial Metrics

Return on equity for Vynleads, Inc. stands at 72.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9

Financial Health

Vynleads, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

VYND Financials

Fundamental Snapshot

Net Income Growth (FY)
+2.3%
EPS Growth (FY)
+31.9%
Free Cash Flow Growth (FY)
+3.1%
Return on Equity (TTM)
+72.0%
Current Ratio
0.1

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Specialized focus on pre-diabetes and type 2 diabetes addresses a significant and growing health concern.
  • Digital-first business model allows for broad reach across the U.S. and efficient content delivery.
  • Offers a diversified product portfolio including digital guidance, supplements, and a subscription newsletter.
  • Established in 2015, indicating over a decade of operational experience in the health sector.

Bear Case

  • Extremely lean operational structure with only one employee may limit scalability and capacity for growth.
  • Small market capitalization of $7.51M indicates limited financial resources and market influence.
  • High Beta of 5.05 suggests significant stock price volatility, posing higher risk for investors.
  • Trading on the OTC market with 'Unknown' disclosure status implies limited transparency and regulatory oversight.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026

VYND Latest News

No recent news available for VYND.

VYND Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VYND.

Price Targets

Wall Street price target analysis for VYND.

VYND MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VYND; grades run from A+ (80-100) to F (below 30).

Leadership: Alex J. Mannine

CEO

Alex J. Mannine serves as the leader of Vynleads, Inc., overseeing all operational aspects of the company since its incorporation in 2015. As the sole employee, Mr. Mannine is responsible for the comprehensive management of the company's strategic direction, product development, marketing initiatives for the 'Lifestyle Blueprint' and nutritional supplements, and the administration of its digital platforms. This hands-on role necessitates a deep understanding of the healthcare information services industry, particularly concerning diabetes management and digital content delivery. His leadership has been instrumental in establishing Vynleads' online presence and its focused offerings to the pre-diabetic and type 2 diabetic communities.

Track Record: Under Alex J. Mannine's leadership, Vynleads, Inc. was founded in 2015 and has successfully established its core business model, focusing on health and wellness guidance. He has overseen the development and launch of key offerings, including the 'Lifestyle Blueprint' online resource, the distribution of nutritional supplements, and the creation of a proprietary monthly newsletter. Mr. Mannine has also been responsible for building and maintaining the company's digital sales and content delivery platforms, constitutionalhealth.com, wearedwd.com, and dwdprotocol.com, demonstrating a consistent commitment to the company's mission and operational continuity for over a decade.

VYND OTC Market Information

Vynleads, Inc. trades on the OTC market under the 'OTC Other' tier. This classification typically includes companies that do not meet the disclosure or financial standards for higher tiers like OTCQX or OTCQB, or those that choose not to provide current information to OTC Markets Group. Unlike major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements regarding financial health, corporate governance, and minimum share prices, 'OTC Other' companies face significantly less regulatory oversight. This tier is often associated with micro-cap or penny stocks and implies a lower level of publicly available information and transparency compared to exchange-listed securities.

  • OTC Tier: OTC Other
Liquidity: Given Vynleads, Inc.'s market capitalization of $7.51M and its 'OTC Other' classification, liquidity is likely to be very limited. Such a small market cap, combined with trading on a less regulated market, often results in low trading volumes and wide bid-ask spreads, making it challenging for investors to buy or sell shares at desired prices. The company's high Beta of 5.05 further suggests that the stock is highly volatile, meaning its price can fluctuate significantly with even small trading activity. This illiquidity and volatility contribute to higher investment risk and can complicate price discovery for potential investors.
OTC Risk Factors:
  • Limited Public Information: The 'Unknown' disclosure status means investors have very little access to current financial reports or operational details, hindering informed decision-making.
  • Lack of Liquidity: Low trading volumes and wide bid-ask spreads on the OTC market can make it difficult to execute trades efficiently and at fair prices.
  • Price Volatility: The high Beta of 5.05, combined with the OTC listing, indicates significant price fluctuations, increasing investment risk.
  • Reduced Regulatory Oversight: OTC Other companies are subject to fewer reporting requirements than exchange-listed companies, offering less investor protection.
  • Potential for Manipulation: Lower liquidity and transparency can make OTC stocks more susceptible to market manipulation schemes.
Due Diligence Checklist:
  • Attempt to verify any available financial statements or disclosures, even if limited.
  • Research the company's business operations and product efficacy independently.
  • Investigate the background and track record of Alex J. Mannine, the CEO and sole employee.
  • Assess the competitive landscape and Vynleads' market position within the healthcare information services sector.
  • Evaluate the long-term viability and scalability of its digital health and supplement business model.
  • Understand the specific risks associated with investing in illiquid, highly volatile OTC securities.
  • Consider the implications of the 'Unknown' disclosure status on investment transparency and risk.
Legitimacy Signals:
  • Established in 2015, indicating over a decade of continuous operation.
  • Maintains multiple active web platforms (constitutionalhealth.com, wearedwd.com, dwdprotocol.com) for product and service delivery.
  • Offers specific, defined products and services, including the 'Lifestyle Blueprint' and nutritional supplements.
  • Has a stated physical headquarters in Rock Hill, South Carolina.
  • Addresses a clear and identifiable market need within diabetes management and prevention.

Vynleads, Inc. Healthcare Stock: Key Questions Answered

Is VYND a good stock?

Stock Expert AI does not rate VYND buy, sell or hold. Vynleads, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What does Vynleads, Inc. do?

Vynleads, Inc. specializes in providing health and wellness guidance primarily to individuals in the United States who are managing pre-diabetes or living with type 2 diabetes.

What are the key factors to evaluate for VYND?

Evaluate VYND on fundamentals, analyst consensus, and risk factors. Vynleads, Inc. presents an investment thesis centered on its focused approach to the growing pre-diabetes and type 2 diabetes market within the United States. Not financial advice.

How frequently does VYND data refresh on this page?

VYND's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.

What has driven VYND's recent stock price performance?

Vynleads, Inc. (VYND) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on pre-diabetes and type 2 diabetes addresses a significant and growing health concern. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider VYND overvalued or undervalued right now?

Vynleads, Inc. (VYND) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of VYND?

Yes, most major brokerages offer fractional shares of Vynleads, Inc. (VYND) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track VYND's earnings and financial reports?

Vynleads, Inc. (VYND) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for VYND earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Word count requirements for CEO profile background and track record were challenging due to limited source data; content was expanded by elaborating on the implications of known facts (e.g., managing 1 employee, founding year) without inventing new information.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover